NBM-HD-1: A novel histone deacetylase inhibitor with anticancer activity

Wei Jan Huang, Yu Chih Liang, Shuang En Chuang, Li Ling Chi, Chi Yun Lee, Chia Wei Lin, Ai Ling Chen, Jing Shi Huang, Chun Jung Chiu, Cheng Feng Lee, Chung Yang Huang, Chia Nan Chen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

HDAC inhibitors (HDACis) have been developed as promising anticancer agents in recent years. In this study, we synthesized and characterized a novel HDACi, termed NBM-HD-1. This agent was derived from the semisynthesis of propolin G, isolated from Taiwanese green propolis (TGP), and was shown to be a potent suppressor of tumor cell growth in human breast cancer cells (MCF-7 and MDA-MB-231) and rat glioma cells (C6), with an IC50 ranging from 8.5 to 10.3M. Western blot demonstrated that levels of p21((Waf1/Cip1)), gelsolin, Ac-histone 4, and Ac-tubulin markedly increased after treatment of cancer cells with NBM-HD-1. After NBM-HD-1 treatment for 14h, p-PTEN and p-AKT levels were markedly decreased. Furthermore, we also found the anticancer activities of NBM-HD-1 in regulating cell cycle regulators. Treatment with NBM-HD-1, p21(Waf1/Cip1) gene expression had markedly increased while cyclin B1 and D1 gene expressions had markedly decreased. On the other hand, we found that NBM-HD-1 increased the expressions of tumor-suppressor gene p53 in a dose-dependent manner. Finally, we showed that NBM-HD-1 exhibited potent antitumor activity in a xenograft model. In conclusion, this study demonstrated that this compound, NBM-HD-1, is a novel and potent HDACi with anticancer activity in vitro and in vivo.

Original languageEnglish
Article number781417
JournalEvidence-based Complementary and Alternative Medicine
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

Histone Deacetylase Inhibitors
bcl-1 Genes
Gelsolin
Propolis
Cyclin B1
Gene Expression
MCF-7 Cells
Tubulin
Tumor Suppressor Genes
Heterografts
Glioma
Antineoplastic Agents
Histones
Inhibitory Concentration 50
Neoplasms
Cell Cycle
Western Blotting
Breast Neoplasms
Growth

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

NBM-HD-1 : A novel histone deacetylase inhibitor with anticancer activity. / Huang, Wei Jan; Liang, Yu Chih; Chuang, Shuang En; Chi, Li Ling; Lee, Chi Yun; Lin, Chia Wei; Chen, Ai Ling; Huang, Jing Shi; Chiu, Chun Jung; Lee, Cheng Feng; Huang, Chung Yang; Chen, Chia Nan.

In: Evidence-based Complementary and Alternative Medicine, Vol. 2012, 781417, 2012.

Research output: Contribution to journalArticle

Huang, WJ, Liang, YC, Chuang, SE, Chi, LL, Lee, CY, Lin, CW, Chen, AL, Huang, JS, Chiu, CJ, Lee, CF, Huang, CY & Chen, CN 2012, 'NBM-HD-1: A novel histone deacetylase inhibitor with anticancer activity', Evidence-based Complementary and Alternative Medicine, vol. 2012, 781417. https://doi.org/10.1155/2012/781417
Huang, Wei Jan ; Liang, Yu Chih ; Chuang, Shuang En ; Chi, Li Ling ; Lee, Chi Yun ; Lin, Chia Wei ; Chen, Ai Ling ; Huang, Jing Shi ; Chiu, Chun Jung ; Lee, Cheng Feng ; Huang, Chung Yang ; Chen, Chia Nan. / NBM-HD-1 : A novel histone deacetylase inhibitor with anticancer activity. In: Evidence-based Complementary and Alternative Medicine. 2012 ; Vol. 2012.
@article{f2268e7d2cff413f8c29dc9bab3c4906,
title = "NBM-HD-1: A novel histone deacetylase inhibitor with anticancer activity",
abstract = "HDAC inhibitors (HDACis) have been developed as promising anticancer agents in recent years. In this study, we synthesized and characterized a novel HDACi, termed NBM-HD-1. This agent was derived from the semisynthesis of propolin G, isolated from Taiwanese green propolis (TGP), and was shown to be a potent suppressor of tumor cell growth in human breast cancer cells (MCF-7 and MDA-MB-231) and rat glioma cells (C6), with an IC50 ranging from 8.5 to 10.3M. Western blot demonstrated that levels of p21((Waf1/Cip1)), gelsolin, Ac-histone 4, and Ac-tubulin markedly increased after treatment of cancer cells with NBM-HD-1. After NBM-HD-1 treatment for 14h, p-PTEN and p-AKT levels were markedly decreased. Furthermore, we also found the anticancer activities of NBM-HD-1 in regulating cell cycle regulators. Treatment with NBM-HD-1, p21(Waf1/Cip1) gene expression had markedly increased while cyclin B1 and D1 gene expressions had markedly decreased. On the other hand, we found that NBM-HD-1 increased the expressions of tumor-suppressor gene p53 in a dose-dependent manner. Finally, we showed that NBM-HD-1 exhibited potent antitumor activity in a xenograft model. In conclusion, this study demonstrated that this compound, NBM-HD-1, is a novel and potent HDACi with anticancer activity in vitro and in vivo.",
author = "Huang, {Wei Jan} and Liang, {Yu Chih} and Chuang, {Shuang En} and Chi, {Li Ling} and Lee, {Chi Yun} and Lin, {Chia Wei} and Chen, {Ai Ling} and Huang, {Jing Shi} and Chiu, {Chun Jung} and Lee, {Cheng Feng} and Huang, {Chung Yang} and Chen, {Chia Nan}",
year = "2012",
doi = "10.1155/2012/781417",
language = "English",
volume = "2012",
journal = "Evidence-based Complementary and Alternative Medicine",
issn = "1741-427X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - NBM-HD-1

T2 - A novel histone deacetylase inhibitor with anticancer activity

AU - Huang, Wei Jan

AU - Liang, Yu Chih

AU - Chuang, Shuang En

AU - Chi, Li Ling

AU - Lee, Chi Yun

AU - Lin, Chia Wei

AU - Chen, Ai Ling

AU - Huang, Jing Shi

AU - Chiu, Chun Jung

AU - Lee, Cheng Feng

AU - Huang, Chung Yang

AU - Chen, Chia Nan

PY - 2012

Y1 - 2012

N2 - HDAC inhibitors (HDACis) have been developed as promising anticancer agents in recent years. In this study, we synthesized and characterized a novel HDACi, termed NBM-HD-1. This agent was derived from the semisynthesis of propolin G, isolated from Taiwanese green propolis (TGP), and was shown to be a potent suppressor of tumor cell growth in human breast cancer cells (MCF-7 and MDA-MB-231) and rat glioma cells (C6), with an IC50 ranging from 8.5 to 10.3M. Western blot demonstrated that levels of p21((Waf1/Cip1)), gelsolin, Ac-histone 4, and Ac-tubulin markedly increased after treatment of cancer cells with NBM-HD-1. After NBM-HD-1 treatment for 14h, p-PTEN and p-AKT levels were markedly decreased. Furthermore, we also found the anticancer activities of NBM-HD-1 in regulating cell cycle regulators. Treatment with NBM-HD-1, p21(Waf1/Cip1) gene expression had markedly increased while cyclin B1 and D1 gene expressions had markedly decreased. On the other hand, we found that NBM-HD-1 increased the expressions of tumor-suppressor gene p53 in a dose-dependent manner. Finally, we showed that NBM-HD-1 exhibited potent antitumor activity in a xenograft model. In conclusion, this study demonstrated that this compound, NBM-HD-1, is a novel and potent HDACi with anticancer activity in vitro and in vivo.

AB - HDAC inhibitors (HDACis) have been developed as promising anticancer agents in recent years. In this study, we synthesized and characterized a novel HDACi, termed NBM-HD-1. This agent was derived from the semisynthesis of propolin G, isolated from Taiwanese green propolis (TGP), and was shown to be a potent suppressor of tumor cell growth in human breast cancer cells (MCF-7 and MDA-MB-231) and rat glioma cells (C6), with an IC50 ranging from 8.5 to 10.3M. Western blot demonstrated that levels of p21((Waf1/Cip1)), gelsolin, Ac-histone 4, and Ac-tubulin markedly increased after treatment of cancer cells with NBM-HD-1. After NBM-HD-1 treatment for 14h, p-PTEN and p-AKT levels were markedly decreased. Furthermore, we also found the anticancer activities of NBM-HD-1 in regulating cell cycle regulators. Treatment with NBM-HD-1, p21(Waf1/Cip1) gene expression had markedly increased while cyclin B1 and D1 gene expressions had markedly decreased. On the other hand, we found that NBM-HD-1 increased the expressions of tumor-suppressor gene p53 in a dose-dependent manner. Finally, we showed that NBM-HD-1 exhibited potent antitumor activity in a xenograft model. In conclusion, this study demonstrated that this compound, NBM-HD-1, is a novel and potent HDACi with anticancer activity in vitro and in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84855182267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855182267&partnerID=8YFLogxK

U2 - 10.1155/2012/781417

DO - 10.1155/2012/781417

M3 - Article

C2 - 22046195

AN - SCOPUS:84855182267

VL - 2012

JO - Evidence-based Complementary and Alternative Medicine

JF - Evidence-based Complementary and Alternative Medicine

SN - 1741-427X

M1 - 781417

ER -